Get started

Biotechnology

Merck has upside to $82Analyst forecasts for Merck earnings came down sharply early this year, but lately they've stabilized and even ticked upward a little. Merck is still priced for an optimistic market, with forward P/E around 15 and PEG around 2-3. This is reasonable for a large cap company with 3% dividend and a great reputation, but it's not bargain pricing, exactly. A second round of lockdowns or a second wave of Covid-19 could hurt the stock again. But as long there's no major deterioration of the macroeconomic outlook, the fair value range for Merck is about $75-82 per share. Analysts have been slow to make any forecasts for 2022 due to macroeconomic uncertainty, but I predict that the top end of the fair value range will shift upward to $87 per share once the 2022 forecasts finally come in. Merck is oversold today on the hourly RSI and curling upward. MACD is below the signal line, but also curling upward. A few minutes ago Merck announced an FDA approval to expand the label for GARDASIL, its HPV drug. I suspect this may function as a catalyst to send Merck back upward toward $82 per share. I bought some shares after-hours, and if I can get in cheap enough, I will consider some call options tomorrow with maybe a one-month expiration.
NYSE:MRKLong
by ChristopherCarrollSmith
3
ONTX - Could Breakout, How Far?All, ONTX is overdue for a takeoff. Today it is at +30% premarket, but this is why you do TA and watch Volume at open. It will gap above both blue lines for support and .44/.45 are aboth huge support lines. My theory is simple it may sell off around .53. However, I would hold and wait for the rally at .39 or .44 to push back up to .70-.75. The question there becomes will it break or fail that area on second re test? ALSO FIRST THING IS FIRST WATCH THE MARKET BEFORE YOU BUY ANY STOCK. S&P / NASDAQ AND WATCH VOLUME ON INVERSE S&P ETFS.
OLong
by DigitalData
$ADAP can rise in the next daysContextual immersion trading strategy idea. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. Friday morning the company presented positive data on its experimental cell therapy, which is designed to treat a range of cancers. It causes a rise in the share price. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $11,85; stop-loss — $11,18. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ADAPLong
by KozakHlib
GNBT: This looks promising to me. I like the major increase in volume. and the EWT look to this. Up about 8% today so far tody. Is a Biotech so is SPECULATIVE so be careful with size of position.. If count is correct there is a possibility of major gains. Bullish candle on the daily chart so far. Could use a close below today's close as a stop. Process your way. From Zacks: Generex Biotechnology Corporation provides research, development, and commercialization of drug delivery systems and technologies. The company's products include Generex Oral-lyn, Glucose RapidSpray, BaBOOM Energy Spray and Crave-NX. It markets its products primarily in Ecuador, Canada, and the United States. Generex Biotechnology Corporation is based in Toronto, Canada.
GLong
by goodguy
$CERC can rise in the next daysContextual immersion trading strategy idea. Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. The company announced it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a proof-of-concept clinical trial of its anti-LIGHT monoclonal antibody CERC-002 in patients with COVID-19 cytokine storm induced Acute Respiratory Distress Syndrome (ARDS). The demand for shares of the company looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $2,97; stop-loss — $2,76. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
CLong
by KozakHlib